Takeda Pharmaceutical (TAK) Projected to Post Quarterly Earnings on Wednesday

Takeda Pharmaceutical (NYSE:TAK) is projected to issue its Q4 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.0754) per share and revenue of $7.1689 billion for the quarter. Parties can check the company’s upcoming Q4 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 6:00 AM ET.

Takeda Pharmaceutical Price Performance

Shares of TAK stock opened at $16.34 on Tuesday. Takeda Pharmaceutical has a 1-year low of $12.99 and a 1-year high of $18.90. The stock’s 50-day moving average is $17.73 and its 200 day moving average is $16.36. The company has a market cap of $51.99 billion, a P/E ratio of 68.07 and a beta of -0.06. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.19 and a quick ratio of 0.65.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on TAK shares. Weiss Ratings restated a “hold (c)” rating on shares of Takeda Pharmaceutical in a research note on Wednesday, April 29th. Sanford C. Bernstein upgraded Takeda Pharmaceutical from a “market perform” rating to an “outperform” rating in a research note on Wednesday, April 8th. Morgan Stanley started coverage on Takeda Pharmaceutical in a research note on Tuesday, January 13th. They set an “overweight” rating on the stock. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. Finally, Wall Street Zen upgraded Takeda Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 11th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Takeda Pharmaceutical has an average rating of “Moderate Buy”.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of TAK. Parkside Financial Bank & Trust lifted its holdings in Takeda Pharmaceutical by 192.2% in the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock valued at $40,000 after acquiring an additional 1,684 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in Takeda Pharmaceutical by 313.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock valued at $48,000 after acquiring an additional 2,328 shares during the period. Northwestern Mutual Wealth Management Co. lifted its holdings in Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after acquiring an additional 1,292 shares during the period. Advisory Services Network LLC acquired a new position in Takeda Pharmaceutical in the third quarter valued at approximately $74,000. Finally, Kestra Advisory Services LLC purchased a new stake in shares of Takeda Pharmaceutical in the fourth quarter valued at approximately $101,000. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.